Anti-Xa levels in critically ill patients receiving dalteparin for thromboprophylaxis.

被引：0
|
作者：
McDonald, E
Dale, C
Pleasance, S
McNeill, A
Harvey, J
Wynne, C
Duffett, M
Provost, L
Rioux, A
LaRouche, G
Davidson, C
Watpool, I
McCardle, T
Foxall, J
Bouwers, K
Lewis, MJ
Zytaruk, N
Griffith, L
Crowther, M
Cook, D
机构：
[1] McMaster Univ, Hamilton, ON L8S 4L8, Canada
[2] Univ Toronto, Toronto, ON, Canada
[3] Dalhousie Univ, Halifax, NS B3H 3J5, Canada
[4] Univ Montreal, Montreal, PQ H3C 3J7, Canada
[5] Univ Laval, Quebec City, PQ, Canada
[6] Univ Ottawa, Ottawa, ON K1N 6N5, Canada
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4075
引用
收藏
页码：105B / 105B
页数：1
相关论文
共 50 条
  • [1] Clinical experience of anti-Xa monitoring in critically ill dogs receiving dalteparin
    Lynch, Alex M.
    deLaforcade, Armelle M.
    Sharp, Claire R.
    [J]. JOURNAL OF VETERINARY EMERGENCY AND CRITICAL CARE, 2014, 24 (04) : 421 - 428
  • [2] THROMBOPROPHYLAXIS USING ANTI-XA LEVELS IN OBESE CRITICALLY ILL PATIENTS: A RETROSPECTIVE STUDY
    Cagliani, Joaquin
    Nio, Kosuma
    Wu, Wenchen
    Smith, Candace
    Park, Jayoung
    Rik, Horacio
    Nicastro, Jeffrey
    Barrera, Rafael
    [J]. CRITICAL CARE MEDICINE, 2016, 44 (12)
  • [3] Effects of dalteparin on anti-Xa levels cannot be predicted in critically ill COVID-19 patients
    Stolk-van der Heijden, Charlotte
    Kooistra, Emma
    ter Heine, Rob
    de Grouw, Elke
    Frenzel, Tim
    Pickkers, Peter
    Leentjens, Jenneke
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 77 (SUPPL 1) : 10 - 11
  • [4] COMPARISON OF ANTI-XA LEVELS BETWEEN OBESE AND NON-OBESE CRITICALLY ILL PATIENTS RECEIVING UNFRACTIONATED HEPARIN THROMBOPROPHYLAXIS
    Blum, Mark
    Park, Jayoung
    Wu, Wenchen
    Belchikov, Yuly
    Smith, Candace
    Barrera, Rafael
    [J]. CRITICAL CARE MEDICINE, 2012, 40 (12) : U254 - U254
  • [5] Anti-Xa Directed Thromboprophylaxis in Critically Ill Patients with Coronavirus Disease 2019
    Mohamed, Adham
    Shemanski, Shelby M.
    Saad, Mohamed O.
    Ploetz, Jeannette
    Haines, Michelle M.
    Schlachter, Andrew B.
    Hamarshi, Majdi S.
    [J]. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2022, 28
  • [6] Anti-Xa Directed Thromboprophylaxis in Critically Ill Patients with Coronavirus Disease 2019
    Mohamed, Adham
    Shemanski, Shelby M.
    Saad, Mohamed O.
    Ploetz, Jeannette
    Haines, Michelle M.
    Schlachter, Andrew B.
    Hamarshi, Majdi S.
    [J]. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2022, 28
  • [7] Anti-Xa levels in critically ill children receiving enoxaparin for venothromboembolism prophylaxis
    Marshall, Amanda M.
    Trussell, Taylor M.
    Yee, Addison M.
    Malone, Mathew P.
    [J]. THROMBOSIS RESEARCH, 2021, 203 : 117 - 120
  • [8] Effects of dalteparin on anti-Xa activities cannot be predicted in critically ill COVID-19 patients
    van der Heijden, Charlotte D. C. C.
    Ter Heine, Rob
    Kooistra, Emma J.
    Bruggemann, Roger J.
    Schmidt, Jesper W. J. Walburgh
    de Grouw, Elke P. L. M.
    Frenzel, Tim
    Pickkers, Peter
    Leentjens, Jenneke
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (06) : 2982 - 2987
  • [9] INFLUENCE OF VARIOUS FACTORS ON ANTI-XA LEVELS IN HOSPITALIZED MEDICAL PATIENTS RECEIVING PARENTERAL THROMBOPROPHYLAXIS
    Papadakis, Ioannis
    Papazachariou, Andria
    Charizani, Aikaterini
    Malikides, Vironas
    Malikides, Onoufrios
    Anagnostakis, Georgios
    Zeniodi, Maria-Eleni
    [J]. JOURNAL OF HYPERTENSION, 2024, 42
  • [10] UTILITY OF SERIAL ANTI-XA MONITORING IN DOGS RECEIVING DALTEPARIN
    Lynch, A. M.
    DeLaforcade, A. M.
    Sharp, C. R.
    [J]. JOURNAL OF VETERINARY INTERNAL MEDICINE, 2012, 26 (03) : 777 - 778
12345